about
68Ga-Based radiopharmaceuticals: production and application relationshipOrgan biodistribution of Germanium-68 in rat in the presence and absence of [(68)Ga]Ga-DOTA-TOC for the extrapolation to the human organ and whole-body radiation dosimetryCharacterization of SnO2-based (68)Ge/ (68)Ga generators and (68)Ga-DOTATATE preparations: radionuclide purity, radiochemical yield and long-term constancyDual PET and Near-Infrared Fluorescence Imaging Probes as Tools for Imaging in Oncology.Prospective of ⁶⁸Ga-radiopharmaceutical development.Phosphinic acid functionalized polyazacycloalkane chelators for radiodiagnostics and radiotherapeutics: unique characteristics and applications.Gallium-68-labeled anti-HER2 single-chain Fv fragment: development and in vivo monitoring of HER2 expression.A monoreactive bifunctional triazacyclononane phosphinate chelator with high selectivity for gallium-68.Comparative gallium-68 labeling of TRAP-, NOTA-, and DOTA-peptides: practical consequences for the future of gallium-68-PET.Fusarinine C, a novel siderophore-based bifunctional chelator for radiolabeling with Gallium-68.A shortcut to high-affinity Ga-68 and Cu-64 radiopharmaceuticals: one-pot click chemistry trimerisation on the TRAP platform.Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA.68Ga-radiolabeled AGuIX nanoparticles as dual-modality imaging agents for PET/MRI-guided radiation therapy.Development of single vial kits for preparation of (68)Ga-labelled peptides for PET imaging of neuroendocrine tumours.Development of a 68Ge/68Ga Generator System Using Polysaccharide Polymers and Its Application in PET Imaging of Tropical Infectious Diseases.
P2860
Q26801794-8A72C4F0-4851-4A36-BC54-7E8CA21E56F0Q36695929-EE1B2ABC-C972-4C5F-89AA-0F643EACEC3DQ36944403-D929EDF9-7B6F-4EC8-A791-A044D1043D7DQ37120903-1A0023A0-A4C6-419C-98F8-57257B20A187Q37435222-904DEC12-DA3A-485D-9E88-260A74EC70A0Q38202090-7709E90B-FBD1-42F5-A738-75CB9DC994BEQ38973014-C7C89A80-43B8-449C-A451-7471DD597E3EQ39332186-ECBC86B8-CC33-456C-BEEC-26307D7088DAQ39605627-BE3E6270-9846-429B-A745-97AE679FA051Q43125421-4F9A54C1-9370-49B8-B140-4BD27FDF8820Q46725531-5B21B737-7E23-44ED-B3E6-BB421270AF84Q48089118-3CFC2CB0-48C6-4351-B5A7-34139F95DC74Q52939850-E52C5803-42E1-4B15-91FF-37F5217470F1Q53081413-DCD86403-67EB-4CF6-87D8-4A19CB87BB32Q55689445-A1356A87-82B4-4C96-A2BB-06F62CED83CE
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Feasibility and availability of ⁶⁸Ga-labelled peptides.
@en
Feasibility and availability of ⁶⁸Ga-labelled peptides.
@nl
type
label
Feasibility and availability of ⁶⁸Ga-labelled peptides.
@en
Feasibility and availability of ⁶⁸Ga-labelled peptides.
@nl
prefLabel
Feasibility and availability of ⁶⁸Ga-labelled peptides.
@en
Feasibility and availability of ⁶⁸Ga-labelled peptides.
@nl
P2860
P1476
Feasibility and availability of ⁶⁸Ga-labelled peptides
@en
P2093
Alfons Verbruggen
Roger D Pickett
P2860
P2888
P304
P356
10.1007/S00259-011-1988-5
P478
39 Suppl 1
P577
2012-02-01T00:00:00Z